Crossmark

Terazosin activates Pgk1 and Hsp90 to promote stress resistance

Crossref DOI link: https://doi.org/10.1038/nchembio.1657

Published Online: 2014-11-10

Published Print: 2015-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chen, Xinping

Zhao, Chunyue http://orcid.org/0000-0003-0889-7871
Li, Xiaolong

Wang, Tao

Li, Yizhou

Cao, Cheng

Ding, Yuehe

Dong, Mengqiu

Finci, Lorenzo

Wang, Jia-huai

Li, Xiaoyu

Liu, Lei
License Information

Text and Data Mining valid from 2014-11-10
More Information

Article History

Received: 9 November 2013

Accepted: 27 August 2014

First Online: 10 November 2014

Competing interests

: The authors declare competing financial interests for the novel use of TZ and its related chemicals to target Pgk1 and their related disease treatments. The authors have patented TZ for related disease treatments under patent numbers ZL 2011 1 0413931.0 and 201110412182.X at the Chinese Patent Office.